Myleran 2 mg Film-coated tablets
PDF Leaflet Revision Date: 5 March 2020
Clinical Summary
Quick overview from the medicine insert
Indication
Palliative treatment of chronic myelogenous leukaemia.
Dosage (summary)
Induction: 0.06 mg/kg/day (max 4 mg). Maintenance: 0.5 to 2 mg/day.
Special Populations
- Obese patients
- Paediatric patients
Pregnancy & Breastfeeding
Contraindicated in pregnancy and lactation; teratogenic effects noted.
Key Drug Interactions
- Azole antifungals
- Thioguanine
- Phenytoin
- Cyclophosphamide
Contraindications
- Hypersensitivity to busulfan
- Resistance to busulfan
- Concomitant use with live vaccines
Common side effects
- Leukopenia
- Thrombocytopenia
- Nausea
- Vomiting
- Diarrhoea
Counselling Points
- Monitor blood counts regularly
- Avoid live vaccines
- Consider sperm preservation in men
Serious warnings
- Risk of pulmonary toxicity
- Bone marrow aplasia
- Hepatic veno-occlusive disease
Important Disclaimer
The Myleran 2 mg Film-coated tablets professional information leaflet below is the property of Pharmacare Limited and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
